Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
Date:5/16/2011

er Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca as a result of the successful completion of the research collaboration portion of the agreements, and secondarily to a non-cash, non-operating expense of $1.3 million, which represents the increase in estimated fair value of the warrant liability.  

RevenueFor the quarter ended March 31, 2011, Palatin recognized $0.1 million of contract revenue under its license and collaboration agreement with AstraZeneca, compared to $2.6 million for the same period in 2010.

Costs and ExpensesTotal operating expenses for the quarter ended March 31, 2011 were $2.7 million compared to $4.6 million for the comparable quarter of 2010.  The net decrease in operating expenses for the quarter was primarily due to Palatin's previously disclosed realignment of resources and reduction in staffing levels in 2010.

Cash positionPalatin's cash and cash equivalents were $22.0 million as of March 31, 2011, compared to cash, cash equivalents and investments of $8.9 million at June 30, 2010, with current liabilities of $1.9 million as of March 31, 2011 compared to $2.4 million as of June 30, 2010.  

The increase in cash and cash equivalents is attributable to Palatin's previously announced completion of its $23.0 million public offering in which Palatin sold 23,000,000 shares of its common stock, Series A warrants to purchase up to 2,000,000 shares of its common stock, and Series B warrants to purchase up to 21,000,000 shares of its common stock.  The net proceeds to Palatin, after deducting underwriting discounts and commissions and other offering expenses, were approximately $21.1 million.  

The Company believes, based on its current operating plan, that its cash and cash equivalents as of March 31, 2011 will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Pala
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... , July 24, 2014 SRI International has ... the National Institute of Allergy and Infectious Diseases (NIAID), ... preclinical development of potential therapies for HIV infection and ... treat HIV and AIDS and the complications and opportunistic ... for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014  Neogen Corporation (Nasdaq: NEOG ... its potential revenue from new rodenticide research are premature. ... analysts on July 22, 2014, Neogen,s CEO commented about ... research. "It was my intent Tuesday at ... of a new type of rodenticide, but certainly not ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2
... 2009 ... ... 2009 -- IntertechPira has teamed up with Carbonfund.org to create a zero-carbon event. ... those emissions to make the event carbon neutral by supporting energy efficiency, renewable energy ...
... , , SAN DIEGO, CA, July 30, ... second quarter 2009 financial results on Tuesday, August 4, 2009 before the ... conference call with a live Internet broadcast that will provide a corporate ... day at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time). , ...
... , , ALPHARETTA, Ga., ... recently announced the appointment of Philip Vogt as Executive Vice ... brings more than thirty years of pharmaceutical experience and ... Prior to this role, Vogt served as President of Ethex ...
Cached Biology Technology:Biopolymers Symposium 2009 Teams with Carbonfund.org to Create a Zero-Carbon Event 2SENOMYX, INC. SECOND QUARTER 2009 EARNINGS CONFERENCE CALL SCHEDULED FOR AUGUST 4, 2009 2
(Date:7/24/2014)... animal species for food or commercial food sale, has ... the decline of many species of primates and other ... than half of the species being consumed are birds, ... not only the meat made available for sale but ... by hunters and brought to villages for consumption, we ...
(Date:7/24/2014)... Imagine a smog-free Los Angeles, where electric cars ply ... run on heat from beneath the earth, from howling ... new Stanford study finds that it is technically and ... one powered by clean, renewable energy. Published in ... sustainable, inexpensive and reliable energy supply in California that ...
(Date:7/24/2014)... team of researchers has developed a new nanoscale agent ... method for assessing the function and properties of the ... diagnosis and treatment of gut diseases. , ... syndrome and inflammatory bowel disease all occur in the ... patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2
... Advanced Computing Center (TACC) at the University of Texas ... support a world-class supercomputer with comprehensive computing and visualization ... possible by a $27.5 million grant from the National ... the NSF "eXtreme Digital" (XD) program, an integrating system ...
... immobilize and devour amphibian prey many times their size. Now ... of Zoology, has discovered that they have an additional advantage ... adult counterparts, have a unique method for luring and feeding ... sirens who lured Ulysses, sailors to their demise, larvae have ...
... genetic variant may explain why some people with asthma do ... medicine for long-term asthma control. Researchers found that asthma patients ... only one-third as well to steroid inhalers as those with ... association study, funded by the National Heart, Lung, and Blood ...
Cached Biology News:Stampede charges computational science forward in tackling complex societal challenges 2Stampede charges computational science forward in tackling complex societal challenges 3Stampede charges computational science forward in tackling complex societal challenges 4Amphibians: Beware young beetles' deadly 'siren call' 2NIH-funded study connects gene variant to response to asthma drugs 2
... loxP-PGK-gb2-neo-loxP template is designed to allow ... cells. The loxP-PGK-gb2-neo-loxP template encodes ... a prokaryotic promoter (gb2) for expression ... a eukaryotic promoter (PGK) for expression ...
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSOS-4 Orbital Shaker is designed ... to provide a uniform motion that is both ... The VSOS-4 Orbital Shaker provides a smooth, quiet, ... for a wide range of laboratory applications such ...
Biology Products: